SummitTX Capital’s Boston Scientific BSX Stock Holding History

SummitTX Capital’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-29,576	Closed	-$2.89M	–	712
2025 Q3	$2.89M	Sell	29,576 -42,705	-59%	-$4.42M	0.12%	190
2025 Q2	$7.76M	Buy	72,281 +1,595	+2%	+$161K	0.33%	63
2025 Q1	$7.13M	Buy	+70,686	New	+$7.12M	0.31%	71

Other funds holding BSX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

SummitTX Capital's BSX Position: Q4 2025 in Review

SummitTX Capital sold out of Boston Scientific (BSX) in Q4 2025, closing a stake of 29,576 shares — an estimated $2.89M sold.

SummitTX Capital first reported a position in BSX in Q1 2025 and held it in 3 quarters. The position peaked at $7.76M in Q2 2025. 1,795 funds tracked by Wall St. Rank hold BSX as of Q4 2025.

SummitTX Capital reported no remaining Boston Scientific position as of Q4 2025 after selling out during the quarter.
SummitTX Capital sold 29,576 Boston Scientific shares in Q4 2025, an estimated $2.89M.
SummitTX Capital first reported a position in Boston Scientific in Q1 2025 and held it in 3 quarters.
SummitTX Capital's Boston Scientific position peaked at $7.76M in Q2 2025.
1,795 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2025.

Based on SummitTX Capital's 13F filing for Q4 2025, filed 17 Feb 2026.